Celgene Announces Clinical Data Evaluating Broad Range Of Blood Cancers To Be Presented At European Hematology Association 2017
Presentations highlight innovative research in multiple disease areas including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that data from a broad range of company-sponsored and investigator-initiated studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 22nd European Hematology Association annual meeting in Madrid, Spain, from June 22-25, 2017.
“Research into blood cancers is at a pivotal point, where we’re able to apply insights into the biology of disease to help evolve the treatment pathways, as well as continue to deepen our understanding of the disease in ways that have the potential to positively impact patients’ lives,” said Michael Pehl, President, Hematology and Oncology for Celgene. “The studies being shared this year illustrate our ongoing commitment to delivering innovative therapies to patients with serious and sometimes underserved blood cancers.”
This year’s data presented at EHA will support the role of Celgene therapies as the foundation of myeloma research, including data evaluating REVLIMID® (lenalidomide) across a variety of patient settings ranging from newly diagnosed to those receiving maintenance treatment following autologous hematopoietic stem cell transplant. The data also highlight the potential of Celgene treatments across a range of blood cancers such as lymphoma, MDS and beta-thalassemia. Findings from key Celgene research collaborations will also be presented, including updated data from the Phase I dose escalation and expansion study of IDHIFA® (enasidenib) in patients with relapsed/refractory acute myeloid leukemia and an isocitrate dehydrogenase-2 mutation.